Of the patients treated with tacrolimus in this study, two developed the common cold and one developed oesophageal
candidiasis that required discontinuation of the drug. Patients recovered from all these episodes of infection. Since tacrolimus
is usually administered to RA patients at doses lower than those recommended in transplant recipients, infection is likely to be less of a safety concern with the use of tacrolimus in the treatment of RA, as suggested by previous studies [3, 4, 10, 11].